Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The knowledge of chronic lymphocytic leukemia (CLL) has progressively deepened during the last forty years. Research activities and clinical studies have been remarkably fruitful in novel findings elucidating multiple aspects of the pathogenesis of the disease, improving CLL diagnosis, prognosis and treatment. Whereas the diagnostic criteria for CLL have not substantially changed over time, prognostication has experienced an expansion with the identification of new biological and genetic biomarkers. Thanks to next-generation sequencing (NGS), an unprecedented number of gene mutations were identified with potential prognostic and predictive value in the 2010s, although significant work on their validation is still required before they can be used in a routine clinical setting. In terms of treatment, there has been an impressive explosion of new approaches based on targeted therapies for CLL patients during the last decade. In this current chemotherapy-free era, BCR and BCL2 inhibitors have changed the management of CLL patients and clearly improved their prognosis and quality of life. In this review, we provide an overview of these novel advances, as well as point out questions that should be further addressed to continue improving the outcomes of patients.

Details

Title
The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment
Author
Pérez-Carretero, Claudia 1   VIAFID ORCID Logo  ; González-Gascón-y-Marín, Isabel 2   VIAFID ORCID Logo  ; Rodríguez-Vicente, Ana E 1   VIAFID ORCID Logo  ; Quijada-Álamo, Miguel 1 ; Hernández-Rivas, José-Ángel 3   VIAFID ORCID Logo  ; Hernández-Sánchez, María 1   VIAFID ORCID Logo  ; Hernández-Rivas, Jesús María 4   VIAFID ORCID Logo 

 Cancer Research Center (IBMCC) CSIC-University of Salamanca, 37007 Salamanca, Spain; [email protected] (C.P.-C.); [email protected] (A.E.R.-V.); [email protected] (M.Q.-Á.); Instituto de Investigación Biomédica (IBSAL), 37007 Salamanca, Spain; Department of Hematology, University Hospital of Salamanca, 37007 Salamanca, Spain 
 Department of Hematology, Infanta Leonor University Hospital, 28031 Madrid, Spain; [email protected] (I.G.-G.-y-M.); [email protected] (J.-Á.H.-R.) 
 Department of Hematology, Infanta Leonor University Hospital, 28031 Madrid, Spain; [email protected] (I.G.-G.-y-M.); [email protected] (J.-Á.H.-R.); Department of Medicine, Complutense University, 28040 Madrid, Spain 
 Cancer Research Center (IBMCC) CSIC-University of Salamanca, 37007 Salamanca, Spain; [email protected] (C.P.-C.); [email protected] (A.E.R.-V.); [email protected] (M.Q.-Á.); Instituto de Investigación Biomédica (IBSAL), 37007 Salamanca, Spain; Department of Hematology, University Hospital of Salamanca, 37007 Salamanca, Spain; Department of Medicine, University of Salamanca, 37008 Salamanca, Spain 
First page
853
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20754418
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2532327197
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.